Top 20 Radiopharmaceutical Companies of 2025

Shots:

Imaging, precision diagnostics, and targeted therapies are among the many ways radiopharmaceuticals improve patient outcomes and meet unmet healthcare needs
In 2024, the global radiopharmaceuticals market was valued at $6.74B and is envisioned to grow to $13.67B by 2033, exhibiting a CAGR of 8.2% from 2024 to 2033. Lilly ranks first in our list with a market cap of 783.76B, followed by Novartis ($233.78B) and RayzeBio ($120.16B) respectively
PharmaShots brings a condensed report on the Top 20 Radiopharmaceutical Companies of 2025, based on market cap

20. Cellectar Biosciences

Market Cap: 16.59M

Founded Year: 1996

Total Employees: 11

Headquarters: New Jersey, United States

Stock Exchange: NASDAQ

Cellectar Biosciences is a late-stage biopharmaceutical company known for developing cancer therapies leveraging its proprietary Phospholipid Drug Conjugate (PDC) delivery platform
The company’s lead candidate Iopofosine is under development for various oncology indications
In November 2024, Cellectar Biosciences and NorthStar Medical Radioisotopes entered into a strategic partnership for the Supply of Actinium-225

19. Oncoinvent

Market Cap: 18.09M

Founded Year: 2010

Total Employees: 35

Headquarters: Oslo, Norway

Stock Exchange: FRA

Oncoinvent is a radiopharmaceutical company focused on developing targeted radiation therapies for the treatment of cancer
Oncoinvent's lead candidate, Radspherin, is an alpha-radiation therapy used to treat cancers that have spread to body cavities
In December 2024, Oncoinvent collaborated with ARTBIO on radiopharma laboratory facilities

18. Radiopharm Theranostics

Market Cap: 38.45M

Founded Year: 2021

Total Employees: 20

Headquarters: Sydney, Australia

Stock Exchange: NASDAQ

Radiopharm Theranostics is a biotechnology company specializing in the development of radiopharmaceuticals for the diagnosis and treatment of unmet medical needs
RAD 101 is the company’s lead asset, currently being evaluated in the P-II study for brain mets
In December 2024, Radiopharm Theranostics entered a strategic co-development partnership with Lantheus to advance developments of radiopharmaceuticals in Australia

17. OncoTherapy Science

Market Cap: 48.74M

Founded Year: 2001

Total Employees: 54

Headquarters: Kawasaki City, Japan

Stock Exchange: TYO

OncoTherapy Science is a biopharmaceutical company focused on the discovery, development, and commercialization of cancer therapies
OncoTherapy’s asset OTSA101 is being evaluated in the P-I study for Synovial Sarcoma in Japan
In 2024, the company completed the enrollment for the P-I study of OTSA101 and confirmed the safety and tolerability of radioisotope-conjugated OTSA101 in refractory, relapsed, and/or advanced synovial sarcoma patients

16. Actinium Pharmaceuticals

Market Cap: 58.34M

Founded Year: 2000

Total Employees: 37

Headquarters: New York, United States

Stock Exchange: NYSE

Actinium Pharmaceuticals is a biotechnology company focused on developing Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies for cancer
Actinium's lead candidate Actimab-A is under development for relapsed/refractory AML and myeloid malignancies
In July 2024, Actinium reported the IND application clearance by the US FDA to study Iomab-ACT for targeted conditioning before a bone marrow transplant, in patients with sickle cell disease

15. Perseus Proteomics

Market Cap: 93.02M

Founded Year: 2001

Total Employees: 25

Headquarters: Tokyo, Japan

Stock Exchange: TYO

Perseus Proteomics is a biotechnology company focused on advancing the field of proteomics to better understand disease mechanisms and develop therapeutic antibodies
The company is developing its radiopharmaceutical candidate PPMX-T002 for the treatment of solid tumor
In October 2024, Perseus Proteomics presented a presentation of PPMX-T002 at the EANM’24 annual congress

14. Dongwha Pharmaceutical

Market Cap: 117.1M

Founded Year: 1897

Total Employees: 816

Headquarters: Seoul, South Korea

Stock Exchange: KRX

Dongwha Pharmaceutical is a South Korean pharmaceutical company that specializes in the development, manufacturing, and distribution of a wide range of pharmaceutical products
The company has one marketed radiopharmaceutical product Milican injection used in the treatment of hepatocellular carcinoma and hemophiliac arthritis
In September 2024, Dongwha Pharmaceutical acquired Hironic, an aesthetic medical device manufacturer

13. Clarity Pharmaceuticals

Market Cap: 459.97M

Founded Year: 2010

Total Employees: 50

Headquarters: New South Wales, Australia

Stock Exchange: ASX

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on developing targeted radio therapies in oncology
The company's lead radiopharmaceutical candidate SAR-bisPSMA is being developed for prostate cancer
In November 2024, the company reported the dosing of the first 2 participants with Cu-64 SAR-bisPSMA in Co-PSMA study

12. Eckert & Ziegler AG

Market Cap: 1.21B

Founded Year: 1997

Total Employees: 1,143

Headquarters: Berlin, Germany

Stock Exchange: ETR

Eckert & Ziegler AG is focused on the development, manufacturing, and distribution of radiation technology and isotopes for medical, scientific, and industrial applications
The company markets Yttriga, an Yttrium Chloride sterile solution that is registered as a medicinal product in the EU
In November 2024, Eckert & Ziegler received EC approval for Theralugand Lutetium-177 Chloride

11. Jubilant Pharmova

Market Cap: 1.63B

Founded Year: 1978

Total Employees: 3,618

Headquarters: Uttar Pradesh, India

Stock Exchange: NSE

Jubilant Pharmova is a global pharmaceutical company that is part of the Jubilant Life Sciences Group. The company operates into three segments: Specialty Pharmaceuticals (Radiopharmaceuticals), Allergy Therapy Products and CDMO
HICON and RUBY-FILL are among the various radiopharmaceutical products that the company offers
In October 2024, Jubilant Radiopharma and Life Molecular Imaging entered into a strategic collaboration and licensing agreement to provide and distribute Neuraceq in Alabama

10. PeptiDream

Market Cap: 1.84B

Founded Year: 2006

Total Employees: 732

Headquarters: Kanagawa, Japan

Stock Exchange: TYO

PeptiDream is a biotechnology company focused on the discovery and development of peptide-based therapeutics by leveraging its proprietary platform: Peptide Discovery Platform System (PDPS)
64Cu-ATSM is the lead asset of the company that is being developed for malignant brain tumors in collaboration with LinqMed and prostate cancer with Curium
In December 2024, Peptidream disclosed a new candidate PD-29875, a peptide-radioisotope conjugate targeting Claudin 18.2 (CLDN18.2)

9. Telix Pharmaceuticals

Market Cap: 5.86B

Founded Year: 2015

Total Employees: 535

Headquarters: Melbourne, Australia

Stock Exchange: ASX

Telix Pharmaceuticals is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals for the diagnosis and treatment of cancer and other unmet needs
The company markets Illuccix, a radiopharmaceutical product for PET scans in prostate cancer, and has several radiopharmaceutical candidates in development, including TLX592 (225Ac–RADmAb) and TLX250 (177Lu–girentuximab)
In October 2024, the US FDA accepted the NDA for Telix’s TLX101-CDx (Pixclara) and granted priority review with a PDUFA action date of 26 April 2025

8. Lantheus

Market Cap: 6.74B

Founded Year: 1956

Total Employees: 808

Headquarters: Massachusetts, United States

Stock Exchange: NASDAQ

Lantheus is a global radiopharmaceutical company specializing in the development, manufacturing, and commercialization of radio therapies and precision diagnostic products
The company's key products include PYLARIFY, DEFINITY and TECHNELITE
In July 2024, Lantheus acquired Meilleur Technologies and added NAV-4694, a ß Amyloid PET Imaging Agent for Alzheimer’s Disease to its product portfolio

7. BWXT Medical (BWX Technologies)

Market Cap: 9.35B

Founded Year: 1867

Total Employees: 8,700

Headquarters: Virginia, United States

Stock Exchange: NYSE

BWXT Medical is a division of BWX Technologies focused on the development and manufacturing of medical isotopes for diagnostic imaging and therapeutic applications
The company markets Indium-111 Oxyquinoline Solution & Sodium Iodide I-123 Oral Solution with several other radiopharmaceuticals in its pipeline
In July 2024, BWXT Medical and NorthStar Medical Radioisotopes entered into a Master Services Agreement to facilitate the production of actinium-225 (Ac-225)

6. Bayer

Market Cap: 24.14B

Founded Year: 1863

Total Employees: 92,815

Headquarters: Leverkusen, Germany

Stock Exchange: ETR

Bayer is a global life science company that operates under three business segments: crop science, pharmaceuticals, and consumer health. The company's therapeutic area focuses on cardiology, gynecology, diabetes, oncology, and ophthalmology
Bayer markets Xofigo (radium Ra 223 dichloride), a radiopharmaceutical to treat prostate cancer that has spread to the bones (bone metastases) in adult men
In February 2024, Bayer entered into a capacity reservation agreement with PanTera for the supply of actinium-225

5. GE Healthcare

Market Cap: 37.04B

Founded Year: 1994

Total Employees: 53,000

Headquarters: Illinois, United States

Stock Exchange: NASDAQ

GE Healthcare is a global leader in medical technologies and healthcare solutions, specializing in delivering imaging, diagnostics, and patient monitoring systems
The company develops several molecular imaging agents, including DaTscan, Vizamyl, and more
In December 2024, GE HealthCare agreed to acquire full ownership of Nihon Medi-Physics by purchasing a 50% stake from Sumitomo Chemical

4. Siemens Healthineers

Market Cap: 61.38B

Founded Year: 1847

Total Employees: 73,100

Headquarters: Bavaria, Germany

Stock Exchange: ETR

Siemens Healthineers is a global MedTech company that provides a wide range of healthcare solutions, including diagnostic imaging, laboratory diagnostics, and digital health services
Siemens’ radiopharmaceutical portfolio includes Ammonia N13, Amyvid and more
In December 2024, Siemens Healthineers acquired advanced accelerator applications molecular imaging from Novartis

3. RayzeBio (BMS)

Market Cap: 120.16B

Founded Year: 1887

Total Employees: 34,100

Headquarters: New York, United States

Stock Exchange: NYSE

RayzeBio is a biotechnology company focused on developing targeted therapies for cancer, using radiopharmaceuticals
Currently the company pipeline includes three radiopharmaceutical candidates: RYZ101, RYZ801, and RYZ811 being developed for various indications
In June 2024, RayzeBio paused the P-III (ACTION-1) study evaluating RYZ101 due to an isotope shortage

2. Novartis

Market Cap: 233.78B

Founded Year: 1996

Total Employees: 75,883

Headquarters: Basel City, Switzerland

Stock Exchange: NYSE

Novartis is a global healthcare company focused on the discovery, development, and commercialization of therapies in cardiovascular, renal, metabolic (CRM), immunology, neuroscience, and oncology
Lutathera and Pluvicto are the two radiopharmaceutical products that company markets
In November 2024, Novartis entered into a license and collaboration agreement with Ratio Therapeutics for SSTR2-targeting radiotherapeutic candidate for cancer

1. Eli Lilly

Market Cap: 783.76B

Founded Year: 1876

Total Employees: 47,000

Headquarters: Indiana, United States

Stock Exchange: NYSE

Eli Lilly is an American pharmaceutical company that specializes in bone and joint disease, cancer, cardiovascular disease, diabetes, endocrine illness, immunology, neurodegeneration, neurology, and pain management
The company’s pipeline includes one radiopharmaceutical candidate: 225Ac-PSMA-62 PNT2001 that is being developed for prostate cancer
In July 2024, Eli Lilly entered into a strategic agreement with Radionetics Oncology to advance Radionetics’ proprietary GPCR targeting small molecule radiopharmaceuticals

Sources: